# Research Study of Visilizumab for Treatment of Glucocorticoid- Refractory Graft Versus Host Disease

> **NCT00032279** · PHASE2 · UNKNOWN · sponsor: **Fred Hutchinson Cancer Center** · enrollment: 80 (—)

## Conditions studied

- Graft-vs-Host Disease

## Interventions

- **DRUG:** Visilizumab

## Key facts

- **NCT ID:** NCT00032279
- **Lead sponsor:** Fred Hutchinson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2002-03
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** 80 (—)
- **Last updated:** 2005-06-24

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00032279

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00032279, "Research Study of Visilizumab for Treatment of Glucocorticoid- Refractory Graft Versus Host Disease". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00032279. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*